Prognostic factors in Hungarian breast cancer patients

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 279-282

  Nádasi, Edit ^a   Anga, Béla ^b   Sándor, János ^c   Megyesi, Judit ^d   Kelemen, Dezso ^a   Mottolese, Marcella ^e   Natali, Pier Giorgio ^e   Hegedus, Géza ^b   Arany, István ^d   Ember, István ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Baranya County Hospital   (Hungary)

^c Department of Pathology ^*  (Hungary)

^d CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Activated extracellular signal regulated kinase; Breast cancer; Immunohistochemistry; Odds ratio; Prognostic factors

Indexed keywords

CYCLOOXYGENASE 2; HORMONE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ELDERLY CARE; GENE MUTATION; HUMAN; HUMAN TISSUE; HUNGARY; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYCLOOXYGENASE 2; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; HUNGARY; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 33847666567     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Harris RE, Namboodiri KK and Farrar WB: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7: 203-205, 1996.
2. Harris RE, Namboodiri KK and Farrar WB: Epidemiological study of nonsteroidal antiinflammatory drugs and breast cancer. Oncol Rep 2: 591-592, 1995.
3. Hwang D, Scollard D, Byrne J and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Canc Inst 90(6): 455-460, 1998.
4. Liu CH, Chang S-H, Narko K, Trifan OC, Wu M-T, Smith E, Haudenschild C, Lane TF and Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21): 18563-18569, 2001.
5. Watanabe O, Shimizu T, Imamura H, Kinoshita J, Utada Y, Okabe T, Kimura K, Hirano A, Yoshimatsu K, Motohiko A and Ogawa K: Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res 23: 3215-3222, 2003.
6. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Corgnati A, Sperotto L, Recaldin E, Spagnolli P, Manfrin E, Bonetti A, Nortilli R, Tomezzoli A, Pollini GP, Modena S and Cetto GL: Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 45: 241-249, 1997.
7. Xu R, Feiner H, Li P, Yee H, Inghirami G, Delgado Y and Perle MA: Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast. Arch Pathol Lab Med 127: 1458-1464, 2003.
8. Ansquer Y, Mandelbrot L, Lehy T, Salomon L, Dhainaut C, Madelenat P, Feldmann G and Walker F: Expression of BRCA1, HER-1 (EGFR) and HER2 in sporadic breast cancer and relationships to other clinicopathological prognostic features. Anticancer Res 25(6C): 4535-4542, 2005
9. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K and Gerber B: Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 25(3A): 1719-1724, 2005
10. Crawford L, Pim D and Lamb P: The cellular protein p53 in human tumors. Mol Biol Med 2: 261-267, 1984.
11. Koutselini H, Malliri A, Field JK and Spandidos DA: p53 expression in cytologic specimens from benign and malignant breast lesions. Anticancer Res 11: 1415-1420, 1991.
12. Schimmelpenning H, Eriksson ET, Pallis L, Skoog L, Cedermark B and Auer GU: Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary carcinoma in situ. Am J Clin Pathol 97(5 Suppl 1): S48-S52, 1992.
13. Hung MC and Lau YK: Basic science of HER-2/neu: a review. Semin Oncol 26: 51-59, 1999.
14. Molina R, Filella X, Zanon G, Pahisa J, Alicaret J, Munoz M, Farrus B and Ballesta AM: Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA15.3) in patients with locoregional breast cCancer. Anticancer Res 23: 1043-1050, 2003.
15. Kato T, Kameoka S, Kimura T, Nishikawa T and Kobayashi M: c-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer. Anticancer Res 22: 1097-1104, 2002.
16. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK and Dowsett M: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17(10): 3058-3063, 1999.
17. Jones S, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, Brooks B, Kerr R, Denham C, Savin M, White C, Blum J, Kirby R, Stone M, Pippen J, Kitchens L, George T, Cooper B, Peters G, Knox S, Grant M, Cheek H, Jones R, Kuhn J, Lieberman Z, Savino D and Rietz C: Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients. Clin Breast Cancer 1(4): 310-317, 2001.
18. Keen JC and Davidson NE: The biology of breast carcinoma. Cancer 97(3Suppl): 825-833, 2003.
19. Graham JD, Roman SD, McGowan E, Sutherland RL and Clarke CL: Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells. J Biol Chem 270: 30693-30700, 1995.
20. Walker RA and Dearing SJ: Expression of epidermal growth factor receptor mRNA and protein in primary breast cancer. Breast Cancer Res Treat 53(2): 167-176, 1999.
21. Subbaramaiah K, Norton L, Gerald W and Dannenberd AJ: Cyclooxygenase-2 is overexpressed in HER2/neu-positive breast cancer. J Biol Chem 277(21): 18649-18657, 2002.
22. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK and McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206, 1993.
23. Rudas M, Neumayer R, Gnant MFX, Mittelbock M, Jakesz R and Reiner A: p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 33(1): 39-44, 1997.
24. Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A, Iff A and Lohrs U: EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 79: 187-198, 2003.
25. Malara NM, Leotta A, Sidoti A, Lio S, D'Angelo R, Caparello B, Munao F, Pino F and Amato A: Aging, hormonal behaviour and cyclin D1 in ductal breast carcinomas. Breast 15(1): 81-89, 2006.
26. Jayasinghe UW, Taylor R and Boyages J: Is age at diagnosis an independent prognostic factor for survival following breast cancer? ANZ J Surg 75(9): 762-767, 2005.
27. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L and Hortobagyi GN: Targeted therapy in breast cancer: the HER-2 neu gene and protein. Mol Cell Proteomics 3(4): 379-398, 2004.
28. Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P and Gorgoulis VG: Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. Anticancer Res 24(3B): 2061-2068, 2004.
29. Fehm T, Becker S, pergola-Becker G, Kramer B, Gruber I, Sotlar K, Kurek R, Wallwiener D and Solomayer E: Influence of tumor biological factors on tumor cell dissemination in primary breast cancer. Anticancer Res 24(6): 4211-4216, 2004.
30. Fehm T, Jager W, Kramer S, Sohn C, Solomayer E, Wallwiener D and Gebauer G: Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 24(3B): 1987-1992, 2004.
31. Sivaraman VS, Wang HY, Nuovo GJ and Malbon CC: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483, 1997.
32. Salh B, Marotta A, Matthewson C, Ahluwalia M, Flint J, Owen D and Pelech S: Investigation of the MEK-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res 19: 731-740, 1999.
33. Milde-Langosch K, Bamberger A-M, Rieck G, Grund D, Hemminger G, Muller V and Loning T: Expression and prognostic relevance of activated extracellular-regullated kinases (ERK1/2) in breast cancer. Br J Cancer 92: 2206-2215, 2005.